OCULAR

EIGHT ESSENTIAL SUSTAINABILITY TERMS FOR THE MEDICAL DEVICE INDUSTRY

EIGHT ESSENTIAL SUSTAINABILITY TERMS FOR THE MEDICAL DEVICE INDUSTRY

Kay Sinclair, Brennan Miles and Charlie Dean provide an overview of eight terms key to a common understanding in the ongoing, and crucial, discussion surrounding sustainability.

OVERCOMING DEVELOPMENT OBSTACLES TO THE DELIVERY OF EFFECTIVE OCULAR THERAPY

OVERCOMING DEVELOPMENT OBSTACLES TO THE DELIVERY OF EFFECTIVE OCULAR THERAPY

Robert Lee discusses the growth of the ocular drug delivery market, the challenges formulators face in developing novel ocular technologies, and the role contract development and manufacturing organisations have to play in this growing market segment.

OPHTHALMIC DRUGS: PATHWAY TO OVERCOME PRIMARY PACKAGING AND DRUG PRODUCT MANUFACTURING CHALLENGES

Rainer Glockler

OPHTHALMIC DRUGS: PATHWAY TO OVERCOME PRIMARY PACKAGING AND DRUG PRODUCT MANUFACTURING CHALLENGES

Rainer Glöckler, Carole Delauney, Dr Nicolas Eon and Katsuyuki Takeuchi discuss the myriad complexities of developing drug products for intravitreal injection, and how the partnership between swissfillon and Terumo can ease and accelerate these products to market. The first article, published in April, covered how swissfillon’s state-of-the-art filling line meets the complex requirements of ophthalmic drug products.

CONSIDERATIONS FOR OPHTHALMIC DRUG DELIVERY AND DEVELOPMENT

CONSIDERATIONS FOR OPHTHALMIC DRUG DELIVERY AND DEVELOPMENT

Robert Lee discusses recent advances in ophthalmic dosage forms and how companies are meeting these challenges to better serve their customers.

STATE-OF-THE-ART SOLUTIONS FOR OPHTHALMIC STERILE DRUG PRODUCT MANUFACTURING

Rainer Glockler

STATE-OF-THE-ART SOLUTIONS FOR OPHTHALMIC STERILE DRUG PRODUCT MANUFACTURING

In the first in a series of two articles, Rainer Glöckler and Carole Delauney discuss how the company’s state-of-the-art filling line meets the requirements and complexities that are particular to ophthalmic drug product manufacturing. The second article, to be published in May, will explore partnerships between pharma, CDMOs and syringe manufacturers in more detail.

THE PIVOTAL ROLE PLAYED BY DEVICE DEVELOPERS TO IMPROVE PATIENT EYE CARE

THE PIVOTAL ROLE PLAYED BY DEVICE DEVELOPERS TO IMPROVE PATIENT EYE CARE

Zoë Davidson and Carolyn Rose discuss the challenges glaucoma and dry eye patients face with eye drop administration and present the Novelia^® system featuring patented PureFlow^® technology, which controls the medication flow.

DRUG DELIVERY TO THE EYE: OVERCOMING THE CHALLENGES OF INTRAVITREAL PREFILLED SYRINGES

Dr Suresh Gupta

DRUG DELIVERY TO THE EYE: OVERCOMING THE CHALLENGES OF INTRAVITREAL PREFILLED SYRINGES

Suresh Gupta discusses the challenges of developing a PFS product for intravitreal injection, highlighting how designing for the intravitreal space, rather than the standard parenteral, imposes a number of additional requirements on the design.

INTERVIEW WITH SAI SHANKAR, ADAM SHAIN & MARCUS BATES

INTERVIEW WITH SAI SHANKAR, ADAM SHAIN & MARCUS BATES

Sai Shankar, Adam Shain and Marcus Bates discuss the full potential of connectivity, coronavirus as a potential accelerator of adoption, and the place of connected drug delivery systems within Aptar Pharma’s broader offering to industry.

EU MDR DEADLINE DELAY: WHAT DOES IT MEAN FOR THE MEDICAL DEVICE INDUSTRY?

EU MDR DEADLINE DELAY: WHAT DOES IT MEAN FOR THE MEDICAL DEVICE INDUSTRY?

With the compliance deadline for the EU Medical Device Regulation recently delayed by a year due to the novel coronavirus pandemic, Beth Crandall looks at what it means for the medical device industry.

INTERVIEW WITH DR SRI MUDUMBA, SANTEN & DR GAUTAM SHETTY, CONGRUENCE

Dr Gautam Shetty

Congruence Medical Solutions

INTERVIEW WITH DR SRI MUDUMBA, SANTEN & DR GAUTAM SHETTY, CONGRUENCE

In this interview, Dr Sri Mudumba, Santen, and Dr Gautam N Shetty, Congruence Medical Solutions, share insights from their experience of working together in developing the MDS for ophthalmic injections.

OPTIMISING OPHTHALMIC DRUG DELIVERY FOR THERAPEUTIC EFFECTIVENESS

Dr Barbara Morgan

OPTIMISING OPHTHALMIC DRUG DELIVERY FOR THERAPEUTIC EFFECTIVENESS

Barbara Morgan discusses how eye physiology impacts product formulation and choice of dosage form, and how advanced delivery technologies are providing new options for formulators seeking to improve the bioavailability or stability of their ophthalmic treatments.

DEVELOPING AN EFFICIENT OPHTHALMIC DEVICE COMBINATION PRODUCT

DEVELOPING AN EFFICIENT OPHTHALMIC DEVICE COMBINATION PRODUCT

Zoë Davidson looks at how understanding the patient journey can help develop an efficient ophthalmic device combination product.

DELIVERING ON THE GROWING NEED FOR TOPICAL PRESERVATIVE-FREE OPHTHALMIC TREATMENTS

Matthias Birkhoff

DELIVERING ON THE GROWING NEED FOR TOPICAL PRESERVATIVE-FREE OPHTHALMIC TREATMENTS

Matthias Birkhoff provides an overview of existing ophthalmic delivery technologies and progress made within topically applied medications – and introduces a new market standard for testing microbial integrity in preservative-free formulation.

ADVANCED DRUG DELIVERY FOR DRY EYE TREATMENT

ADVANCED DRUG DELIVERY FOR DRY EYE TREATMENT

Rouven Kraus and Wilfried Woesthuis discuss Aero Pump and Medspray's new open-eye spray for the treatment of dry eyes.

THE CURRENT STATE OF PLAY IN CONNECTED DEVICES

THE CURRENT STATE OF PLAY IN CONNECTED DEVICES

Marcus Bates; Joachim Koerner and Jerôme Prraquin discuss the current state of play, what connected device advocates are doing to enable faster implementation, and how we can optimise connected technology while reducing the cost and improving human factors.

USING MARKET RESEARCH TO CREATE A PRESERVATIVE-FREE MULTIDOSE EYEDROPPER

Silgan Dispensing

USING MARKET RESEARCH TO CREATE A PRESERVATIVE-FREE MULTIDOSE EYEDROPPER

Thomas Grinnan and Ralf Hergenröther explain how extensive market research and consumer testing led to the development of an eyedropper that meets patients’ and physicians’ needs for an easy-to-use device, which offers precise dosing and anti-microbial integrity.

USER TESTING: CRITICAL FOR TRULY UNDERSTANDING PATIENT NEEDS

USER TESTING: CRITICAL FOR TRULY UNDERSTANDING PATIENT NEEDS

Fanny Sellier presents a trio of comparative user studies between Nemera’s Novelia^® preservative-free, multidose eyedropper and similar products from competitors

ACCURATE, PRECISE MICROLITRE DOSING WITH PREFILLABLE SYRINGES FOR OPHTHALMIC INJECTIONS

Dr Gautam Shetty

Congruence Medical Solutions

ACCURATE, PRECISE MICROLITRE DOSING WITH PREFILLABLE SYRINGES FOR OPHTHALMIC INJECTIONS

Gautam Shetty discusses the challenges inherent to delivering microlitre dosage volumes accurately from a standard prefilled syringe, and introduces Congruence’s Microlitre Dosing Syringe (MDS) platform as a solution.

BREAKING THE VICIOUS CIRCLE OF DRY EYE DISEASE

Dr Christian Roesky

BREAKING THE VICIOUS CIRCLE OF DRY EYE DISEASE

Christian Roesky discusses the underserved condition of dry eye disease, and presents two products in Novaliq’s pipelinefor the treatment of different types of DED.

KEEPING PRESERVATIVE-FREE EYEDROPS STERILE WITH THE STERIDROP™ TUBE

KEEPING PRESERVATIVE-FREE EYEDROPS STERILE WITH THE STERIDROP™ TUBE

Ralf Künzi introduces the SteriDrop™ tube – a new multidose eyedrop delivery solution made in collaboration with Aptar Pharma.

THE CHALLENGES AND OPPORTUNITIES OF DRUG DELIVERY THROUGH A COMPLEX BARRIER

THE CHALLENGES AND OPPORTUNITIES OF DRUG DELIVERY THROUGH A COMPLEX BARRIER

Jon Volmer, Marc Brown and Jeremy Drummond discuss the development and use of advanced ex vivo and in vitro models for testing new ocular medicines to meet a growing unmet need.

TARGETING DRUGS TO DISEASED OCULAR CELLS

Frazer P Coutinho

TARGETING DRUGS TO DISEASED OCULAR CELLS

Frazer Coutinho, Colin Green and Ilva Rupenthal discuss the targeted delivery of ocular therapeutics to diseased cells, using the cell-penetrating peptide, Xentry.

INTRAVITREAL INJECTION OF VEGF INHIBITORS – IMPACT OF DRUG CONTAINERS

INTRAVITREAL INJECTION OF VEGF INHIBITORS – IMPACT OF DRUG CONTAINERS

With the increasing use of intravitreal injections of vascular endothelial growth factor inhibitors in the treatment of numerous serious ocular diseases, Douglas Cusato provides a detailed comparative analysis of the issues at play.

ACUSTREAM™: BRINGING TOPICAL OPHTHALMIC DRUG DELIVERY INTO THE MODERN ERA

Dr Peter Noymer

ACUSTREAM™: BRINGING TOPICAL OPHTHALMIC DRUG DELIVERY INTO THE MODERN ERA

Peter Noymer, Ehud Ivri, Reynaldo Quintana and Mark Blumenkranz introduce AcuStream, a novel device for next-generation delivery of topical ophthalmic delivery via an aim-assisted stream.

Prev
1
2
3
4
5
6
Next

Top